5 results match your criteria: "New York Eye and Ear Infirmary at Mount Sinai School of Medicine[Affiliation]"
Ophthalmology
April 2015
Einhorn Clinical Research Center, New York Eye and Ear Infirmary at Mount Sinai School of Medicine, New York.
Ophthalmology
February 2015
Einhorn Clinical Research Center, New York Eye and Ear Infirmary at Mount Sinai School of Medicine, New York, New York.
Mol Vis
June 2015
Department of Ophthalmology and Visual Sciences, University of Michigan, Ann Arbor, MI.
Purpose: To identify the cause of congenital cataracts in a consanguineous family of Ashkenazi Jewish ancestry.
Methods: We performed genome-wide linkage analysis and whole-exome sequencing for the initial discovery of variants, and we confirmed the variants using gene-specific primers and Sanger sequencing.
Results: We found significant evidence of linkage to chromosome 22, under an autosomal dominant inheritance model, with a maximum logarithm of the odds (LOD) score of 3.
Transl Vis Sci Technol
September 2014
Inspire Pharmaceuticals, Durham, North Carolina.
Purpose: To evaluate the safety, tolerability, and intraocular pressure (IOP)-lowering effect of Latrunculin-B (Lat-B), a marine macrolide that disrupts the actin cytoskeleton, in patients with ocular hypertension (OHT) or early primary open-angle glaucoma (POAG).
Methods: In this Phase I, multicenter, double-masked, randomized, placebo-controlled, ascending-dose study, subjects with bilateral OHT or early POAG (>22 mm Hg) received one of four concentrations of INS115644 (Lat-B ophthalmic solutions, 0.005%, 0.
Ophthalmology
October 2014
Einhorn Clinical Research Center, New York Eye and Ear Infirmary at Mount Sinai School of Medicine, New York, New York; Department of Ophthalmology, New York University Medical Center, New York, New York.
Objective: The objective of this prospective, longitudinal study of patients with normal-tension glaucoma (NTG) was to determine whether patients with nocturnal hypotension are at greater risk for visual field (VF) loss over 12 months than those without nocturnal hypotension.
Design: Prospective, longitudinal study.
Participants: Consecutive patients with NTG with at least 5 prior VF tests were screened for eligibility.